-
No penalty practice? No problem for Man City in shoot-out win
-
Argentine football fan jailed for threats over Di Maria return
-
Microsoft beats expectations fueled by Azure cloud business
-
Liverpool beat Chelsea in League Cup shoot-out, Man City survive scare
-
Chelsea win as Bayern draw with Madrid in Women's Champions League
-
Inter leave it late again in Serie A as AC Milan, Juventus lose
-
Kane watches as Bayern cruise into German Cup last 16
-
Shares in Google owner Alphabet plummet on profit miss, ad slowdown
-
Bayern boss Kompany out of hospital after meningeal irritation
-
Putin hails Elon Musk as 'truly a genius'
-
Shares in Google owner Alphabet sink on profit miss, ad slowdown
-
US stocks eye big tech earnings as Fed holds rates steady
-
Chelsea win as Bayern and Madrid draw in Women's Champions League
-
US Fed holds interest rates steady despite 'too high' inflation
-
Made with munitions from the Falklands War, a 'Chalice of Peace' for the pope
-
Rwanda cannot be blamed for what happens in DR Congo, FM says
-
Pioneering US labor leader Dolores Huerta dies at 96
-
Inter leave it late again in Serie A as Bologna sink AC Milan
-
Italian PM slams 'shameful' release of alleged protest organiser
-
Bolsonaro's escape to the US: How it happened
-
Hollywood producer Kennedy to head LA28 Olympic ceremony plans
-
Russell calls on Scotland to 'kick on' and beat big teams
-
Djokovic wins Basel opener to boost ATP Finals bid
-
Airbus aims for record deliveries despite disappointing quarter
-
US Fed holds interest rates steady despite surging inflation
-
Cuba wins UN vote against US embargo with weakest backing in 30 years
-
Chiefs sign ex-Ravens kicker suspended over sex allegations
-
Real Madrid, La Liga apology over Mbappe shows power of Chinese market
-
Inglis and Carey put Australia in command of South Africa decider
-
From Gaza to Ramallah, Palestinians see little hope in Israeli vote
-
92-year-old US judge handling Maduro case dies
-
US labor leader Dolores Huerta dead: family
-
Perez extends Cadillac deal to 2029
-
Investors turn cautious ahead of tech results, Fed update on rates
-
Arab Israelis proud of high election turnout, uncertain for future
-
'Cruise for life' strands passengers in Cambodia as operator goes bust
-
Inglis, Carey put Australia in command of South Africa decider
-
Bolsonaro flees Brazil for US after election defeat
-
French firm Safran helps build aircraft wings of the future in UK factory
-
A throne on wheels, popemobiles star in new Vatican show
-
Ceasefire in Russia-occupied Ukrainian city holds for second day
-
Spain high-speed train crash kills 68, injures over 100
-
Canada hikes rates to contain oil price surge caused by Iran war
-
UK woman drugged by husband tells rape trial she woke up bound
-
World Bank warns of worsening food insecurity as commodity prices soar
-
Clean-up starts as Serbian students movement prepares to govern
-
Mona Lisa scrubbed from Syrian textbooks as critics slam conservative drift
-
Flavio Bolsonaro: right-wing heir falls from presidential hopeful to exile
-
Bolsonaro flees Brazil for US after election defeat: AFP
-
UK budget lifts bank tax to offset surging energy bills
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB